Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-µg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic
Bin Yao, MS
Advertisement
Articles by Bin Yao, MS
Advertisement
Latest Updated Articles
- Clinical Trial Simulation of a 200-µg Fixed Dose of Darbepoetin Alfa in Chemotherapy-Induced Anemia
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
